For Nancy Dreyer, red flags were visible in the two COVID-19 observational studies retracted by prominent journals. She pointed out the suspicious details to show others where problems could emerge when evaluating studies using real-world evidence.
“When I talk to people they say, 'Well, if reviewers from the New England Journal and the Lancet couldn’t spot...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?